## Edgar Filing: CEL SCI CORP - Form 8-K

CEL SCI CORP Form 8-K September 17, 2009

> UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

> > FORM 8-K

#### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): September 16, 2009

CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter)

0-11503 84-0916344 Colorado \_\_\_\_\_ (State or other jurisdiction (Commission File No.) (IRS Employer of incorporation) Identification No.)

> 8229 Boone Boulevard, Suite 802 Vienna, Virginia 22182 \_\_\_\_\_\_

(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (703) 506-9460

N/A

(Former name or former address if changed since last report)

#### Item 1.01 Entry Into a Material Definitive Agreement

On September 16, 2009 CEL-SCI Corporation sold 14,285,715 shares of its common stock to a group of private investors for \$20,000,000 or \$1.40 per share. The investors also received Series D warrants which entitle the investors to purchase 4,714,284 shares of CEL-SCI's common stock. The Series D warrants may be exercised at any time prior to September 21, 2011 at a price of \$1.50 per share. The closing of the transaction is expected to close on or before September 21, 2009.

CEL-SCI has agreed to pay Rodman & Renshaw, LLC, the placement agent for this offering, a cash commission of \$1,000,000, as well as an expense reimbursement of \$37,500. CEL-SCI has also agreed to issue to Rodman & Renshaw

# Edgar Filing: CEL SCI CORP - Form 8-K

714,286 Series E warrants. Each Series E warrant will entitle the holder to purchase one share of CEL-SCI's common stock. The Series E warrants may be exercised at any time prior to August 12, 2014 at a price of \$1.75 per share.

CEL-SCI has filed with the Securities and Exchange Commission a prospectus supplement to its shelf Registration Statement on Form S-3 registering the shares of common stock and warrants sold to the private investors.

Item 9.01 Financial Statements and Exhibits

Exhibit Number	Description
5	Opinion of Counsel
10 (m)	Securities Purchase Agreement, together with schedule required by Instruction 2 to Item 601 of Regulation S-K, and the form of the Series D warrant, which is an exhibit to the Securities Purchase Agreement.
10(n)	Placement Agent Agreement
23(a)	Consent of Attorneys

2

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 16, 2009 CEL-SCI CORPORATION

By: /s/ Geert R. Kersten
Geert R. Kersten, Chief Executive Officer

CEL-SCI CORPORATION

FORM 8-K

EXHIBITS